I came across this press release for IGI, Inc., a New Jersey based company that is “committed to growth by applying proprietary technologies to achieve cost-effective solutions for varied customer needs.” (Is that management double-speak or what?) Their technologies focus on methods of delivering skin care products, and their customer list includes big names such as Johnson & Johnson and Estee Lauder.
Here’s the point of relevence, from the press release:
IGI is also exploring the licensing of the topical PTH (7-34) compound for the prevention/treatment of chemotherapy induced-alopecia in patients undergoing chemotherapy.
PTH, that is parathyroid hormone, therapies may have the ability …read more